John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting

Public release date: 7-Dec-2012
[ | E-mail | Share ]

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center

Nearly one-third of the studies will be presented orally at this premier hematology research conference

Hackensack, N.J. (December 6, 2012) Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit jtcancercenter.org/ash2012.

John Theurer Cancer Center 2012 ASH Abstracts:

Lymphoma

• 59 A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL), Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 1:00 PM
• 471 Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT, Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 11:00AM
• 686 The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study, Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 4:45 PM
• 895 SOX11 Directly Represses Wnt/?-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment, K. Stephen Suh, PH.D., Oral session: Dec. 11, 2012 Time: 7:30AM
• 904 Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:15 AM
• 905 Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:30 AM
• 1579 Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome, Anthony R. Mato, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 1623 A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2728 Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort, Tatyana Feldman, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 2751 Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib, Andre Goy, MD, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3120 Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3638 Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3658 Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3659 Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group, Burton Appel, MD, Oral and Poster sesson: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3678 Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4269 Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Multiple Myeloma

• 331 Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 7:00AM
• 450 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 11:45AM
• 727 MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 4:30 PM
• 2962 A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials, David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3104 A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM), Scott Rowley, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 4036 A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4038 MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4053 Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT), David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4070 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4072 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Stem Cell Transplantation

• 457 Multicenter Study of "off-the-Shelf" Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT), Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 10:00AM
• 738 Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome Updated Results of a Treatment IND (T-IND) Expanded Access Protocol, Alfred P. Gillio III, MD, Oral Session: Dec. 10, 2012 Time: 5:45PM
• 1965 Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT), David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 3041 Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP), Alfred P. Gillio III, MD, Oral and Poster session: Dec 9, 2012 Time: 6:00-8:00PM
• 3054 Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation, Robert Korngold, PhD, Oral and Poster Session: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3710 Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4106 Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model, Robert Korngold, PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Leukemia

• 1685 Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey, Stuart L. Goldberg, M.D, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Stuart L. Goldberg, M.D, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM

Hematologic Malignancies

• 203 A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies, David S. Siegel, M.D., PH.D., Oral session: Dec. 9, 2012 Time: 5:30PM
• 1936 Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies, Melissa F Baker, APN, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM

###

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertiseall under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Media Contact:

Amy Leahing
305.458.0599
aleahing@p4strategy.com

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 7-Dec-2012
[ | E-mail | Share ]

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center

Nearly one-third of the studies will be presented orally at this premier hematology research conference

Hackensack, N.J. (December 6, 2012) Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit jtcancercenter.org/ash2012.

John Theurer Cancer Center 2012 ASH Abstracts:

Lymphoma

• 59 A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL), Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 1:00 PM
• 471 Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT, Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 11:00AM
• 686 The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study, Andre Goy, MD, Oral Session: Dec. 12, 2012 Time: 4:45 PM
• 895 SOX11 Directly Represses Wnt/?-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment, K. Stephen Suh, PH.D., Oral session: Dec. 11, 2012 Time: 7:30AM
• 904 Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:15 AM
• 905 Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study, Andre Goy, MD, Oral Session: Dec. 11, 2012 Time: 8:30 AM
• 1579 Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome, Anthony R. Mato, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 1623 A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2728 Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort, Tatyana Feldman, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 2751 Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib, Andre Goy, MD, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3120 Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3638 Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma, Andre Goy, MD, Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3658 Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3659 Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942: A Report From the Children's Oncology Group, Burton Appel, MD, Oral and Poster sesson: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 3678 Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4269 Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population, Anthony R. Mato, M.D., M.S.C.E., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Multiple Myeloma

• 331 Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 7:00AM
• 450 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis, David S. Siegel, M.D., PH.D., Oral session: Dec. 10, 2012 Time: 11:45AM
• 727 MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 4:30 PM
• 2962 A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials, David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3104 A Phase I/II Study of Escalating Doses of Thalidomide (Thal) in Conjunction with Bortezomib (Vel) and High Dose Melphalan (Mel) As A Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Patients with Advanced Multiple Myeloma (MM), Scott Rowley, M.D., Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 4036 A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4038 MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study, David Siegel, MD, PhD, Oral and Poster session: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4053 Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT), David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4070 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4072 Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes, David S. Siegel, M.D., PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Stem Cell Transplantation

• 457 Multicenter Study of "off-the-Shelf" Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT), Scott Rowley, M.D., Oral session: Dec. 10, 2012 Time: 10:00AM
• 738 Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome Updated Results of a Treatment IND (T-IND) Expanded Access Protocol, Alfred P. Gillio III, MD, Oral Session: Dec. 10, 2012 Time: 5:45PM
• 1965 Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT), David H. Vesole, M.D., PH.D., F.A.C.P., Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 3041 Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP), Alfred P. Gillio III, MD, Oral and Poster session: Dec 9, 2012 Time: 6:00-8:00PM
• 3054 Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation, Robert Korngold, PhD, Oral and Poster Session: Dec. 9, 2012 Time: 6:00 PM-8:00 PM
• 3710 Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant, Tatyana Feldman, M.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM
• 4106 Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model, Robert Korngold, PH.D., Poster: Dec. 10, 2012 Time: 6:00 PM-8:00 PM

Leukemia

• 1685 Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey, Stuart L. Goldberg, M.D, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM
• 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Stuart L. Goldberg, M.D, Poster: Dec. 9, 2012 Time: 6:00 PM-8:00 PM

Hematologic Malignancies

• 203 A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies, David S. Siegel, M.D., PH.D., Oral session: Dec. 9, 2012 Time: 5:30PM
• 1936 Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies, Melissa F Baker, APN, Poster: Dec. 8, 2012 Time: 5:30 PM-7:30 PM

###

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertiseall under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit jtcancercenter.org.

Media Contact:

Amy Leahing
305.458.0599
aleahing@p4strategy.com

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2012-12/jtcc-jtc120712.php

doppler radar colorado rockies moonshine news channel 4 radar weather morosini death jacoby ellsbury